The role of glutathione peroxidase enzymes in Alzheimer's disease
DOI:
https://doi.org/10.15584/ejcem.2026.2.4Keywords:
Alzheimer’s disease , glutathione peroxidase, neurodegeneration, oxidative stressAbstract
Introduction and aim. Alzheimer’s disease (AD) is a neurodegenerative disorder that affects mainly the elderly. Among the variety of factors contributing to the pathogenesis of AD, oxidative stress has emerged as a key factor in the initiation and progression of the disease. Glutathione peroxidases (GPxs) are enzymes that are known to play a critical role in maintaining cellular redox balance. To this end, the present narrative review aims to explore the role of GPx enzymes in AD and discuss their contribution to oxidative stress pathways and AD pathogenesis.
Literature search. PubMed, Scopus, and Google Scholar were searched for relevant literature. No specific inclusion and exclusion criteria were used due to the narrative nature of the review.
Analysis of the literature. Available records suggest a strong association between oxidative stress and the pathological features of AD, including amyloid-β aggregation, tau hyperphosphorylation, and neuroinflammation. The enzyme isoforms GPx1, GPx3, and GPx4 have been implicated in AD pathogenesis. Conclusions: GPx enzymes play an important protective role in AD. Despite promising preclinical evidence, more translational research is required to clarify the therapeutic and biomarker potential of GPxs in AD.
Downloads
References
Cao Q, Tan CC, Xu W, et al. The prevalence of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2020;73(3):1157-1166. doi:10.3233/jad-191092
Patel B, Walker R, Capó M, et al. A review of Alzheimer’s disease and inflammation: pathogenesis, inflammatory processes, and novel insights from the artificial intelligence perspective. Med Res Arch. 2023;11(7.2). doi:10.18103/mra.v11i7.2.3971
Xiao D, Zhang C. Current therapeutics for Alzheimer’s disease and clinical trials. Explor Neurosci. 2024;3(3):255-271. doi:10.37349/en.2024.00048
Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395(2):203-230. doi:10.1515/hsz-2013-0241
Ionescu-Tucker A, Cotman CW. Emerging roles of oxidative stress in brain aging and Alzheimer’s disease. Neurobiol Aging. 2021;107:86-95. doi:10.1016/j.neurobiolaging.2021.07.014
Dhapola R, Beura SK, Sharma P, Singh SK, HariKrishnaReddy D. Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics. Mol Biol Rep. 2024;51(1):48. doi:10.1007/s11033-023-09021-z
Jurkovic Mlakar S, Osredkar J, Marc J. Molecular impact of glutathione peroxidases in antioxidant processes. Biochem Med. 2008. doi:10.11613/BM.2008.016
Sarikaya E, Doğan S. Glutathione peroxidase in health and diseases. In: Bagatini MD, editor. Glutathione System and Oxidative Stress in Health and Disease. Rijeka: IntechOpen; 2020.
Dhapola R, Beura SK, Sharma P, Singh SK, HariKrishnaReddy D. Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics. Mol Biol Rep. 2024;51(1):48. doi:10.1007/s11033-023-09021-z
Teixeira JP, de Castro AA, Soares FV, da Cunha EFF, Ramalho TC. Future therapeutic perspectives into Alzheimer’s disease targeting the oxidative stress hypothesis. Molecules. 2019;24(23):4410. doi:10.3390/molecules24234410
Tamagno E, Guglielmotto M, Vasciaveo V, Tabaton M. Oxidative stress and beta amyloid in Alzheimer’s disease. Which comes first: the chicken or the egg? Antioxidants (Basel). 2021;10(9). doi:10.3390/antiox10091479
Hussain MS, Agrawal N, Ilma B, et al. Autophagy and cellular senescence in Alzheimer’s disease: key drivers of neurodegeneration. CNS Neurosci Ther. 2025;31(7):e70503. doi:10.1111/cns.70503
Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer’s disease. Biomed Rep. 2016;4(5):519-522. doi:10.3892/br.2016.630
Jiang T, Sun Q, Chen S. Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. Prog Neurobiol. 2016;147:1-19. doi:10.1016/j.pneurobio.2016.07.005
Hussain MS, Khan Y, Fatima R, et al. Microglial modulation in Alzheimer’s disease: central players in neuroinflammation and pathogenesis. Curr Alzheimer Res. 2025;22(1):56-82. doi:10.2174/0115672050364292250113063513
Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr. 2009;3(1):88-93. doi:10.4161/cam.3.1.7402
Margis R, Dunand C, Teixeira FK, Margis-Pinheiro M. Glutathione peroxidase family- an evolutionary overview. FEBS J. 2008;275(15):3959-3970. doi:10.1111/j.1742-4658.2008.06542.x
Liu C, Yan Q, Gao C, Lin L, Wei J. Study on antioxidant effect of recombinant glutathione peroxidase 1. Int J Biol Macromol. 2021;170:503-513. doi:10.1016/j.ijbiomac.2020.12.183
Sharma G, Shin E-J, Sharma N, et al. Glutathione peroxidase-1 and neuromodulation: novel potentials of an old enzyme. Food Chem Toxicol. 2021;148:111945. doi:10.1016/j.fct.2020.111945
Brigelius-Flohé R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 2013;1830(5):3289-3303. doi:10.1016/j.bbagen.2012.11.020
Cardoso BR, Ong TP, Jacob-Filho W, et al. Glutathione peroxidase 1 Pro198Leu polymorphism in Brazilian Alzheimer’s disease patients: relations to the enzyme activity and to selenium status. J Nutrigenet Nutrigenomics. 2012;5(2):72-80. doi:10.1159/000338682
Chu FF, Doroshow JH, Esworthy RS. Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI. J Biol Chem. 1993;268(4):2571-2576. doi:10.1016/S0021-9258(18)53812-6
Esworthy RS, Yang L, Frankel PH, Chu FF. Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient mice. J Nutr. 2005;135(4):740-745. doi:10.1093/jn/135.4.740
Guo B, Liao W, Wang S. The clinical significance of glutathione peroxidase 2 in glioblastoma multiforme. Transl Neurosci. 2021;12:032-039. doi:10.1515/tnsci-2021-0005
Bashir B, Gulati M, Vishwas S, et al. Bridging the gap in the management of Alzheimer’s disease using fecal microbiota transplantation. Mol Cell Neurosci. 2025;135:104052. doi:10.1016/j.mcn.2025.104052
Taj T, Kaushik M, Islam A, et al. Microbiota-brain interaction: the role of gut-derived proteins in addressing various neurological disorders including Parkinson’s (PD) and Alzheimer’s diseases (AD). Biomed Pharmacother. 2025;193:118861. doi:10.1016/j.biopha.2025.118861
Zhao L, Zong W, Zhang H, Liu R. Kidney toxicity and response of selenium containing protein-glutathione peroxidase (Gpx3) to CdTe QDs on different levels. Toxicol Sci. 2019;168(1):201-208. doi:10.1093/toxsci/kfy297
Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018;14:450-464. doi:10.1016/j.redox.2017.10.014
Perri G, Mathers JC, Martin-Ruiz C, et al. The association between selenium status and global and attention-specific cognition in very old adults in the Newcastle 85+ Study: cross-sectional and longitudinal analyses. Am J Clin Nutr. 2024;120(5):1019-1028. doi:10.1016/j.ajcnut.2024.09.004
Kim S, Jung UJ, Kim SR. Role of oxidative stress in blood-brain barrier disruption and neurodegenerative diseases. Antioxidants (Basel). 2024;13(12). doi:10.3390/antiox13121462
Costa I, Barbosa DJ, Benfeito S, et al. Molecular mechanisms of ferroptosis and their involvement in brain diseases. Pharmacol Ther. 2023;244:108373. doi:10.1016/j.pharmthera.2023.108373
Imai H, Matsuoka M, Kumagai T, Sakamoto T, Koumura T. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis. Curr Top Microbiol Immunol. 2017;403:143-170. doi:10.1007/82_2016_508
Cardoso BR, Hare DJ, Bush AI, Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration? Mol Psychiatry. 2017;22(3):328-335. doi:10.1038/mp.2016.196
Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273-285. doi:10.1016/j.cell.2017.09.021
Khan G, Hussain MS, Khan Y, et al. Ferroptosis and its contribution to cognitive impairment in Alzheimer’s disease: mechanisms and therapeutic potential. Brain Res. 2025;1864:149776. doi:10.1016/j.brainres.2025.149776
Yoo M-H, Gu X, Xu X-M, et al. Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer’s disease. Antioxid Redox Signal. 2009;12(7):819-827. doi:10.1089/ars.2009.2891
Ma H, Dong Y, Chu Y, Guo Y, Li L. The mechanisms of ferroptosis and its role in Alzheimer’s disease. Front Mol Biosci. 2022;9:965064. doi:10.3389/fmolb.2022.965064
Mugesh G. Glutathione peroxidase activity of ebselen and its analogues: some insights into the complex chemical mechanisms underlying the antioxidant activity. Curr Chem Biol. 2013;7:47-56. doi:10.2174/2212796811307010005
Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017;266:17-26. doi:10.1016/j.jconrel.2017.09.012
Kryscio RJ, Abner EL, Caban-Holt A, et al. Association of antioxidant supplement use and dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial (PREADViSE). JAMA Neurol. 2017;74(5):567-573. doi:10.1001/jamaneurol.2016.5778
Pereira ME, Souza JV, Galiciolli MEA, et al. Effects of selenium supplementation in patients with mild cognitive impairment or Alzheimer’s disease: a systematic review and meta-analysis. Nutrients. 2022;14(15). doi:10.3390/nu14153205
Pyka P, Garbo S, Fioravanti R, et al. Selenium-containing compounds: a new hope for innovative treatments in Alzheimer’s disease and Parkinson’s disease. Drug Discov Today. 2024;29(8):104062. doi:10.1016/j.drudis.2024.104062
Teixeira JP, de Castro AA, Soares FV, da Cunha EFF, Ramalho TC. Future therapeutic perspectives into Alzheimer’s disease targeting the oxidative stress hypothesis. Molecules. 2019;24(23):4410. doi:10.3390/molecules24234410
Cassidy L, Fernandez F, Johnson JB, Naiker M, Owoola AG, Broszczak DA. Oxidative stress in Alzheimer’s disease: a review on emergent natural polyphenolic therapeutics. Complement Ther Med. 2020;49:102294. doi:10.1016/j.ctim.2019.102294
Zhang H, Zhou W, Li J, et al. Senegenin rescues PC12 cells with oxidative damage through inhibition of ferroptosis. Mol Neurobiol. 2022;59(11):6983-6992. doi:10.1007/s12035-022-03014-y
Baruah P, Moorthy H, Ramesh M, Padhi D, Govindaraju T. A natural polyphenol activates and enhances GPX4 to mitigate amyloid-β induced ferroptosis in Alzheimer’s disease. Chem Sci. 2023;14(35):9427-9438. doi:10.1039/d3sc02350h
Li X, Chen J, Feng W, et al. Berberine ameliorates iron levels and ferroptosis in the brain of 3 × Tg-AD mice. Phytomedicine. 2023;118:154962. doi:10.1016/j.phymed.2023.154962
Auberger P, Favreau C, Savy C, Jacquel A, Robert G. Emerging role of glutathione peroxidase 4 in myeloid cell lineage development and acute myeloid leukemia. Cell Mol Biol Lett. 2024;29(1):98. doi:10.1186/s11658-024-00613-6
Shin EJ, Chung YH, Sharma N, et al. Glutathione peroxidase-1 knockout facilitates memory impairment induced by β-amyloid (1-42) in mice via inhibition of PKC βII-mediated ERK signaling; application with glutathione peroxidase-1 gene-encoded adenovirus vector. Neurochem Res. 2020;45(12):2991-3002. doi:10.1007/s11064-020-03147-3
Pei J, Pan X, Wei G, Hua Y. Research progress of glutathione peroxidase family (GPX) in redoxidation. Front Pharmacol. 2023;14. doi:10.3389/fphar.2023.1147414
Revel F, Gilbert T, Roche S, et al. Influence of oxidative stress biomarkers on cognitive decline. J Alzheimers Dis. 2015;45(2):553-560. doi:10.3233/jad-141797
Oosthoek M, Lili A, Almeida A, et al. ASURE clinical trial protocol: a randomized, placebo-controlled, proof-of-concept study aiming to evaluate safety and target engagement following administration of TW001 in early Alzheimer’s disease patients. J Prev Alzheimers Dis. 2023;10(4):669-674. doi:10.14283/jpad.2023.107
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
